1. Scrip
  2. >>Therapy Areas
  4. >>Immuno-oncology

BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts

 
• By Alaric DeArment

BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.

BMS said it would take control of a Novartis plant in Illinois to manufacture viral vectors for CAR-T • Source: Shutterstock

Bristol Myers Squibb Company is hoping to bolster its manufacturing capacity for autologous chimeric antigen receptor T-cell (CAR-T) therapies with an agreement to take over one of Novartis AG’s manufacturing plants.

The announcement closely follows a contract manufacturing deal that the Swiss drug maker reached with Legend Biotech Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.